Rosetta Defaults on Payment to Prometheus, Faces Bankruptcy | GenomeWeb

By Doug Macron

Despite its early promise as one of the first players in the microRNA diagnostics space, Rosetta Genomics is facing bankruptcy, according to documents filed last month with the US Securities and Exchange Commission.

According to Rosetta, it has defaulted on a $650,000 payment it owed, with interest, to one-time marketing partner Prometheus Laboratories.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.

In Science this week: convergent evolution in bird hemoglobin, and more.

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.